^
    Back
    Association details:
    Biomarker:BRCA wild-type
    Cancer:Triple Negative Breast Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

    Published date:
    04/14/2022
    Excerpt:
    The median duration of response was 7.4 months. Analysis of cfDNA tumor fractions (TFx) revealed that patients with TFx < 15% after completion of the first cycle had a longer progression-free survival compared with those with TFx ≥ 15% (6.0 vs. 0.9 months; P = 0.0001)....Alpelisib in combination with olaparib is tolerable in patients with pre-treated TNBC, with evidence of activity in non-BRCA carriers.
    DOI:
    https://doi.org/10.1158/1078-0432.CCR-21-3045
    Trial ID:
    NCT01623349